NP-2 / Diamyd Medical - LARVOL DELTA

Gene therapy for pain: Results of a phase 1 clinical trial (Neuro Sci 2011) - P1, N=10; Subjects receiving 108 pfu NP2 reported significant decreases in pain to less than 20% of pre-dosing values at 7 and 14 days, after which the numeric rating scale (NRS)began to rise; Patients in the highest dose (109 pfu NP2) reported a similar reduction in pain, which lasted through the 28 day time point

P1 data • Pain

Diamyd Medical: Diamyd puts focus on pain projects and reduces costs (Businesswire) - Results from a P2 study with the furthest developed drug candidate, NP2 Enkephalin for the treatment of severe cancer pain, is expected around year end; The next drug candidate in portfolio, NG2 GAD for treatment of diabetes pain is planned to be ready to enter clinical phase; Company has decided to follow pts who received injections of Diamyd, but not ones who received placebo, for six mos after last injection; The last follow-up visit is planned to take place in December

Anticipated P2 data • Pain

Diamyd Medical reports results from phase II study in cancer pain (Businesswire) - P2, N=33; In P2 study NP2 enkephalin showed no better improvement in pain score vs. PBO; The treatment was well tolerated despite lack of efficacy

P2 data • Pain

Diamyd Medical: Financial Statement 10/11 (Businesswire) - P2 results expected between January and June 2012; The Company plans to begin clinical studies with the next NTDDS-based drug candidate for the treatment of pain, NG2 GAD, after evaluation of the study results with NP2 enkephalin

Anticipated P2 result • Pain